Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.


NDAQ:NVCR - Post by User

Novocure Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Aug 28, 2024 12:02pm
20 Views
Post# 36199551

Novocure to Participate in 2024 Wells Fargo Healthcare Confe

Novocure to Participate in 2024 Wells Fargo Healthcare Confe
Breaking News: $NVCR Novocure to Participate in 2024 Wells Fargo Healthcare ConferenceNovocure (NASDAQ: NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure&#x2019;s Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with inve...NVCR - Novocure to Participate in 2024 Wells Fargo Healthcare Conference

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities